Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin to prevent vascular occlusion in the critically ill
NCT01073800Phase 3Completed
- Sponsor
- University of Alberta
- Start
- Apr 2009
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atorvastatin in Vascular occlusion, myocardial infarction (MI), stroke and 1 more, sponsored by University of Alberta. Primary endpoint: Vascular occlusive events at 30 days. Started Apr 2009; status: completed.
02
Drugs
atorvastatin
03
Conditions
Vascular occlusionmyocardial infarction (MI)strokekidney failure (ESRD)
Beyond the preview
Go deeper on NCT01073800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01073800.